Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer

Next Previous
X
Search
Trial Profile

A Phase 1b Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vantictumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors OncoMed Pharmaceuticals

    • Most Recent Events

    • 25 Jul 2017 Status changed from suspended to completed.
    • 08 May 2017 Status changed from active, no longer recruiting to suspended, according to an OncoMed Pharmaceuticals media release.
    • 08 May 2017 According to an OncoMed Pharmaceuticals media release, the company has put this program on hold. OncoMed has subsequently decided to cease dosing patients in the current vantictumab Phase 1b studies following a recent bone adverse event that occurred in a patient receiving vantictumab plus paclitaxel in the Phase 1b HER2-negative breast cancer trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top